TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Beactica Therapeutics AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
5,651
|
4,960
|
4,906 |
| Financial expenses |
50
|
74
|
73 |
| Earnings before taxes |
-3,191
|
-6,058
|
-7,117 |
| EBITDA |
-3,183
|
-5,872
|
-6,910 |
| Total assets |
20,896
|
20,131
|
24,395 |
| Current assets |
3,471
|
2,872
|
8,604 |
| Current liabilities |
1,534
|
1,591
|
2,888 |
| Equity capital |
19,362
|
18,214
|
20,805 |
| - share capital |
252
|
240
|
225 |
| Employees (average) |
6
|
9
|
8 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
92.7%
|
90.5%
|
85.3% |
| Turnover per employee |
942
|
551
|
613 |
| Profit as a percentage of turnover |
-56.5%
|
-122.1%
|
-145.1% |
| Return on assets (ROA) |
-15.0%
|
-29.7%
|
-28.9% |
| Current ratio |
226.3%
|
180.5%
|
297.9% |
| Return on equity (ROE) |
-16.5%
|
-33.3%
|
-34.2% |
| Change turnover |
855
|
30
|
1,919 |
| Change turnover % |
18%
|
1%
|
64% |
| Chg. No. of employees |
-3
|
1
|
0 |
| Chg. No. of employees % |
-33%
|
13%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.